TTThomas J. Tucker

Thomas J. Tucker

*This is an algorithmically generated author record based on publicly available information.

Thomas J. Tucker has a total of 166 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correction to “Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, Through Issue Driven Fragment-Based Synthetic Assembly and SAR”

    by Hubert Josien, Anilkumar G. Nair, Fa-Xiang Ding, Yan Guo, Yi-Heng Chen, Ashwin U. Rao, Jian Liu, Ling Tong, Zhongxiang Sun, Michael M.-C Lo, et al.

  • Top Cited Papers

    Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR

    by Hubert Josien, Anilkumar G. Nair, Fa-Xiang Ding, Yan Guo, Yi-Heng Chen, Ashwin U. Rao, Jian Liu, Ling Tong, Zhongxiang Sun, Michael M.-C. Lo, et al.

    Herein, we report the discovery process of enlicitide (MK-0616, compound 18), an orally active macrocyclic peptide therapeutic against PCSK9 for LDL-C reduction. To overcome development bottlenecks in a prior lead (compound 1a) in a timely manner (sulfur oxidation liability, low solubility, azido potential manufacturing hazard, and alkene isomeric complexity), we deployed a novel scalable solution-phase modular fragment assembly (North/East/South/West/tail), which allowed us to accelerate the design-make-test-analyze (DMTA) cycle and preclinical profiling. Design solutions were quickly validated through this approach (a northern lactam staple, an N-benzylamide southern spacer, an RCM-derived cross-link in conjunction with solvent-exposed motifs to modulate solubility) and delivered compounds with low picomolar potency, improved solubility, stability, and PK from which enlicitide (MK-0616, compound 18) was selected for clinical progression. This modular strategy may act as a template to accelerate late-stage issue-driven SAR in highly engineered macrocyclic peptides.


  • Integrated In Silico, Ex Vivo, and In Vitro Framework for Early Derisking of Mast Cell Degranulation in Peptide Drug Candidates

    by Falgun Shah, Roujia Wang, Brian A. Vega, Feifei Chen, Bhavana Bhatt, Nicolas C. Boyer, Jennifer Hanisak, Thomas J. Tucker, Shuzhi Dong, Hubert Josien, et al.

    Recent studies have shown that certain peptides and small molecules can induce pseudoanaphylaxis reactions by triggering mast cell degranulation (MCD), resulting in the release of vasoactive and proinflammatory mediators. This mechanism can result in severe adverse drug reactions with potentially life-threatening consequences in humans or loss of tolerability in animal studies, representing a considerable challenge in the development of peptide and small-molecule therapeutics. Therefore, early identification of drug candidates with MCD potential is crucial for an efficient Design-Make-Test-Analyze (DMTA) cycle while promoting the 3Rs principle (replacement, reduction, refinement) in animal research. In the present work, we introduce a proactive risk mitigation strategy aimed at evaluating and minimizing the MCD activity of peptide drug candidates. We developed an ex vivo rat peritoneal mast cell degranulation (rMCD) assay to screen and prioritize candidates that do not exhibit rMCD activity during the lead optimization phase. Importantly, structure-activity relationships (SAR) were established by leveraging rMCD data sets which included ∼3000 diverse peptides across 28 internal programs targeting multiple therapeutic areas. Critical physicochemical properties were identified as predictive calculated parameters for rMCD outcomes. Additionally, we developed a directed message passing neural network (D-MPNN) model that combines structural features with calculated and predicted physicochemical properties, demonstrating strong predictive performance for rMCD outcomes. This model facilitates the early prioritization of peptide drug candidates for rMCD assays during the candidate selection phase and accelerates hit-to-lead and lead optimization by identifying peptides within a series that exhibit minimal rMCD liabilities. Notably, the D-MPNN model outperformed traditional in silico property-based calculators in our prospective validation study. Furthermore, to address species-specific SAR, we also established a human MCD (hMCD) assay, revealing an 80% concordance in MCD outcomes between species. This hMCD assay identifies the MCD liabilities of compounds that differ from those in rats, indicating potential risks in humans. This comprehensive in silico and in vitro approach enables drug discovery teams to advance drug candidates that are free from MCD liability in a resource-efficient manner, thereby increasing the likelihood of success in both nonclinical and clinical studies.


  • Top Cited Papers
    Open Access

    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

    by Douglas G. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G. Bulger, Inne Crevecoeur, Fa-Xiang Ding, et al.

    Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.


  • A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

    by Thomas J. Tucker, Mark W. Embrey, Candice Alleyne, Rupesh P. Amin, Alan Bass, Bhavana Bhatt, Elisabetta Bianchi, Danila Branca, Tjerk Bueters, Nicole Buist, et al.

    Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. Starting from second-generation lead structures such as 2, we were able to refine these structures to obtain extremely potent bi- and tricyclic PCSK9 inhibitor peptides. Optimized molecules such as 44 demonstrated sufficient oral bioavailability to maintain therapeutic levels in rats and cynomolgus monkeys after dosing with an enabled formulation. We demonstrated target engagement and LDL lowering in cynomolgus monkeys essentially identical to those observed with the clinically approved, parenterally dosed antibodies. These molecules represent the first report of highly potent and orally bioavailable macrocyclic peptide PCSK9 inhibitors with overall profiles favorable for potential development as once-daily oral lipid-lowering agents. In this manuscript, we detail the design criteria and multiparameter optimization of this novel series of PCSK9 inhibitors.


  • Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design

    by Candice Alleyne, Rupesh P. Amin, Bhavana Bhatt, Elisabetta Bianchi, J. Craig Blain, Nicolas Boyer, Danila Branca, Mark W. Embrey, Sookhee N. Ha, Kelli Jette, et al.

    Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein–protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the molecular weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease.


  • Open Access

    Novel pH Selective, Highly Lytic Peptides Based on a Chimeric Influenza Hemagglutinin Peptide/Cell Penetrating Peptide Motif

    by Bethany Algayer, Ann O’brien, Aaron Momose, Dennis J. Murphy, William Procopio, David M. Tellers, Thomas J. Tucker

    Delivery of macromolecular cargos such as siRNA to the cytosol after endocytosis remains a critical challenge. Numerous approaches including viruses, lipid nanoparticles, polymeric constructs, and various peptide-based approaches have yet to yield a general solution to this delivery issue. In this manuscript, we describe our efforts to design novel endosomolytic peptides that could be used to facilitate the release of cargos from a late endosomal compartment. These amphiphilic peptides, based on a chimeric influenza hemagglutinin peptide/cell-penetrating peptide (CPP) template, utilize a pH-triggering mechanism in which the peptides are protonated after acidification of the endosome, and thereby adopt an alpha-helical conformation. The helical forms of the peptides are lytically active, while the non-protonated forms are much less or non-lytically active at physiological pH. Starting from an initial lead peptide (INF7-Tat), we systematically modified the sequence of the chimeric peptides to obtain peptides with greatly enhanced lytic activity that maintain good pH selectivity in a red blood cell hemolysis assay.


  • Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses

    by Thomas J. Tucker, John T. Sisko, Robert M. Tynebor, Theresa M. Williams, Peter J. Felock, Jessica A. Flynn, Ming-Tain Lai, Yuexia Liang, Georgia McGaughey, Meiquing Liu, et al.

    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been shown to be a key component of highly active antiretroviral therapy (HAART). The use of NNRTIs has become part of standard combination antiviral therapies producing clinical outcomes with efficacy comparable to other antiviral regimens. There is, however, a critical issue with the emergence of clinical resistance, and a need has arisen for novel NNRTIs with a broad spectrum of activity against key HIV-1 RT mutations. Using a combination of traditional medicinal chemistry/SAR analyses, crystallography, and molecular modeling, we have designed and synthesized a series of novel, highly potent NNRTIs that possess broad spectrum antiviral activity and good pharmacokinetic profiles. Further refinement of key compounds in this series to optimize physical properties and pharmacokinetics has resulted in the identification of 8e (MK-4965), which has high levels of potency against wild-type and key mutant viruses, excellent oral bioavailability and overall pharmacokinetics, and a clean ancillary profile.


  • The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations

    by Thomas J. Tucker, Sandeep Saggar, John T. Sisko, Robert M. Tynebor, Theresa M. Williams, Peter J. Felock, Jessica A. Flynn, Ming-Tain Lai, Yuexia Liang, Georgia McGaughey, et al.


  • The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases

    by Thomas J Tucker, Marc T Abrams, Carolyn A Buser, Joseph P Davide, Michelle Ellis-Hutchings, Christine Fernandes, Jackson B Gibbs, Samuel L Graham, George D Hartman, Hans E Huber, et al.